Forty-seven patients (96%) had a comprehensive FCM analysis to define subtypes according to the 2008 WHO criteria for T-ALL/LBL, based on the status of the pan-T Ag panel: CD1a, CD2, sCD3, CD4, CD5, CD7, and CD8. Here, CD2 is linked to acute lymphoblastic leukemia.